Detalhe da pesquisa
1.
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
BMC Med
; 20(1): 108, 2022 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35379237
2.
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Blood
; 133(11): 1217-1221, 2019 03 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30692124
3.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Blood
; 132(6): 587-597, 2018 08 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29884741
4.
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Blood
; 123(12): 1826-32, 2014 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24421329
5.
Predicting analysis time in events-driven clinical trials using accumulating time-to-event surrogate information.
Pharm Stat
; 15(3): 198-207, 2016 05.
Artigo
Inglês
| MEDLINE | ID: mdl-26689725
6.
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
N Engl J Med
; 366(19): 1759-69, 2012 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-22571200
7.
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
Blood
; 119(12): 2764-7, 2012 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-22323483
8.
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Blood
; 114(4): 772-8, 2009 Jul 23.
Artigo
Inglês
| MEDLINE | ID: mdl-19471019
9.
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
N Engl J Med
; 357(21): 2123-32, 2007 Nov 22.
Artigo
Inglês
| MEDLINE | ID: mdl-18032762
10.
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
N Engl J Med
; 357(21): 2133-42, 2007 Nov 22.
Artigo
Inglês
| MEDLINE | ID: mdl-18032763
11.
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Blood
; 112(12): 4445-51, 2008 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18799726
12.
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
Haematologica
; 95(10): 1738-44, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-20460639
13.
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
Eur J Haematol
; 82(6): 426-32, 2009 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-19302559
14.
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Leukemia
; 33(1): 159-170, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29967379
15.
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
J Clin Oncol
; 35(29): 3279-3289, 2017 Oct 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28742454
16.
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 33(30): 3459-66, 2015 Oct 20.
Artigo
Inglês
| MEDLINE | ID: mdl-26282661
17.
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
Cancer
; 116(16): 3807-14, 2010 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20564094
18.
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
J Pain Symptom Manage
; 38(5): 650-62, 2009 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-19896571
19.
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
J Clin Oncol
; 26(13): 2171-7, 2008 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18362366